Finance Watch: Public Markets Open Back Up For Biopharma Offerings
AN2 Launches First US IPO In More Than A Month
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
You may also be interested in...
Deals Of The Year 2022 Winners Revealed
For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Orion Exits Neuro To Concentrate On Cancer And Pain
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.